Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK2 | Q9HBH9 | 11/20 | 0.84 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.46 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18789196 | 0.87 | MKNK2 (0.82) | MKNK2MKNK1IRAK4 | |
| SCHEMBL24110648 | 0.67 | MTNR1A (0.46) | MKNK2IRAK4 | |
| SCHEMBL18789159 | 0.63 | MKNK2 (0.61) | MKNK2MKNK1IRAK4 | |
| SCHEMBL30404241 | 0.62 | IRAK4 (0.39) | MKNK2IRAK4 | |
| SCHEMBL24110412 | 0.62 | IRAK4 (0.39) | MKNK2IRAK4 | |
| SCHEMBL30762656 | 0.61 | ADORA2A (0.37) | IRAK4 | |
| SCHEMBL27869342 | 0.61 | PIK3CD (0.45) | MKNK2IRAK4 | |
| SCHEMBL18797873 | 0.60 | MKNK2 (0.58) | MKNK2MKNK1IRAK4 | |
| SCHEMBL13827496 | 0.60 | PDK2 (0.51) | — | |
| SCHEMBL30759344 | 0.59 | CACNA1H (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-10-31 | — | — | US | disclosed |
| WO-2017075412-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS INC (US) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | NEK9, NEK2, TYK2 | MKNK2 37/4885MKNK1 67/4885DGAT1 4847/4885 |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | NEK9, NEK2, TYK2 | MKNK2 38/4885MKNK1 67/4885DGAT1 4848/4885 |
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | NEK9, NEK2, TYK2 | MKNK2 37/4885MKNK1 67/4885DGAT1 4847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.